Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.
Alan K BurnettNigel H RussellRobert K HillsStephen KnapperSylvie D FreemanBrian James Patrick HuntlyRichard E ClarkIan F ThomasLars KjeldsenMary Frances Frances McMullinMark DrummondJonathan KellRuth SpearingPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)
Although a fourth course of high-dose Ara-C reduced CIR and improved RFS, it did not result in a significant OS benefit. Subsets including those with favorable cytogenetics, those lacking a mutation of FLT3 or NPM1, or those with < 3 other mutations may derive survival benefit.